Skip to content
DataLookout
Menu

iMMagine-6NCT07903506

To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma

StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. New version filed on ClinicalTrials.gov
  2. Study First Submitted

Endpoints

Primary

Minimal Residual Disease (MRD)-Negative Complete Response (CR) or Stringent CR (sCR) Rate at 12 Months
Timeframe: Up to 12 months
Progression-Free Survival (PFS)
Timeframe: Up to 15 years

Secondary (21)

Overall survival (OS)
Overall Response Rate (ORR)
Rate of Very Good Partial Response or Better
Rate of CR or Better
Time to Response (TTR)
Show 16 moreShow less
Duration of response (DOR)
Time to Progression (TTP)
Percentage of Participants Experiencing Serious Adverse Events (SAEs)
Percentage of Participants Experiencing Adverse Events (AEs)
Percentage of Participants With Anti-Anitocabtagene Autoleucel Chimeric Antigen Receptor (CAR) Antibodies (Anitocabtagene Autoleucel Arm B)
Change From Baseline in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score
Change From Baseline in the European Organisation for Research and Treatment of Cancer (EORTC) - Multiple Myeloma Module (EORTC QLQ-MY20) Scores
Change From Baseline in the European Quality of Life (EuroQoL) 5-Dimension 5-Level (EQ-5D-5L) Scale Index Score
Change From Baseline in the EQ-5D-5L Visual Analog Scale (VAS) Score
Percentages of Participants Responses for Patient Global Impression Scale - Severity (PGI-S)
Percentages of Participants Responses for Patient Global Impression Scale Change (PGI-C)
Percentages of Participants Responses for Functional Assessment of Cancer Therapy Item GP5 (FACT-GP5)
Percentage of Participants With Hospitalizations
Mean Number of Inpatient Days per Hospitalizations
Mean Number of Intensive Care Unit Days per Hospitalizations
Percentage of Participants by Reason for Hospitalization

Arms and interventions

Arm A: Standard of Care Therapy (SOCT)Active comparator

Participants will receive a total of three induction therapy cycles, 42 days for each cycle, with isatuximab, bortezomib, lenalidomide and dexamethasone. Following induction, participants will receive high dose conditioning therapy with melphalan and autologous stem cell transplantation (auto-SCT). Following auto-SCT, participants will receive maintenance therapy with isatuximab and lenalidomide during 28-day cycles for up to 36 cycles or until unacceptable toxicity, disease progression per IMWG criteria, or withdrawal of consent, whichever occurs first.

Arm B: Anitocabtagene AutoleucelExperimental

Participants will receive a total of three induction therapy cycles, 42 days for each cycle, with isatuximab, bortezomib, lenalidomide and dexamethasone. Following induction, participants will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine for 3 days, followed by a single infusion of anitocabtagene autoleucel. Following anitocabtagene autoleucel, participants will receive maintenance therapy with isatuximab and lenalidomide during 28-day cycles for up to 36 cycles or until unacceptable toxicity, disease progression per IMWG criteria, or withdrawal of consent, whichever occurs first.

Drugs: Anitocabtagene Autoleucel, Isatuximab, Bortezomib, Lenalidomide, Dexamethasone, Fludarabine, Cyclophosphamide, Melphalan